Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Teleoncology: Prospects and challenges for cost effective cancer care.
Psychosocial and Communication Research
Symptoms and Survivorship
2019 ASCO Annual Meeting
J Clin Oncol 37, 2019 (suppl; abstr e23182)
Author(s): Ammara Majeed, Midhat Lakhani, Afia Ashraf, Udhayvir Singh Grewal, Prem Thirunagari, Ahsan Wahab, Hamza Hassan, Muhammad Salman Faisal, Fazal I Raziq, Faiz Anwer; Suquino Inc, Sunnyvale, CA; Dow Medical College, Pakistan, Karachi, Pakistan; Anne Arundel Medical Center, Annapolis, MD; Cleveland Clinic, Cleveland, OH; Department of Physiology, The University of Arizona, Tucson, AZ; Baptist Medical Center South/University of Alabama Birmingham, Montgomery, AL; Rochester General Hospital, Rochester, NY; Internal Medicine Allegheny General Hospital, Pittsburgh, PA; Michigan State University, East Lansing, MI; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH
Background: An estimated 20.3 million cancer survivors are expected to be around by 2026. Estimated national expenditure for cancer care in 2017 were $147.3 billion and expected to increase every year. Cancer treatment is complex and requires management decisions, counselling, psychological support to be made by multidisciplinary teams. For rural and remote patients, these teams may be composed of local clinicians, and experts from distant urban centers using telemedicine (TeleMed). Methods: We used 2 databases to study Teleoncology (TelOnc) since 2002. Results: Scope of TelOnc includes cancer Telegenetics, Telepathology, remote supervision, symptom management, survivorship care, palliative care, and increase access to cancer clinical trials. Mobile applications support symptom management, lifestyle modification, and medication adherence. TeleMed can support the oncologist with interactive tele-education. Future TelOnc models would include web-based tools, mobile technologies and remote chemotherapy supervision. TeleMed had a high patient satisfaction rate. In a survey 82.21% participants were satisfied with their TeleMed experience, only 2.14% was not satisfied. Challenges: Despite an area of growing need, few studies have prospectively evaluated its efficacy in cancer. Even fewer data is available in young adults (group with liking for technology) with cancer. Lack of uniform model for reimbursement and hurdles of interstate practice license for providers are unique challenges. Conclusions: TeleMed / TelOnc can improve access to medical care, reduce healthcare costs, (Table) and reduce geographic health disparities.
|Author/Year||User Settings||Outcome||Future growth|
|Cecchini 2016||Face-to-face (FTF) vs. e-consults||18% drop in FTF consults (2 years), Total consults increased by 75% (3 years)||Yes|
|Hede 2010||Economic / Satisfaction analysis FTF vs Videoconferencing n = 200||95% indicated TeleMed was as good as FTF.||Yes|
|Brigden 2008||TelOnc vs. FTF||TelOnc more useful for monitoring vs initial consultations.||Yes|
|Basch 2007||On paper vs. electronic patient reporting (PRO) in cancer clinical trials||On paper information collection was inefficient / error-prone. PROs comprehensive, uses include collection of chemotherapy symptom burden, dose modification, adjustment in supportive medications. Trials regulatory reporting.||Yes|
|Goldberg 2002||Reporting platform||Real-time detection of serious symptoms, outpatient monitoring, research data collection, quality, and care experience.||Yes|